An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

BACKGROUND: Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of glucocorticoid-induced diabetes mellitus. METHODS: From De...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Med Case Rep
Päätekijät: Miyawaki, Yoshia, Sada, Ken-Ei, Asano, Yosuke, Hayashi, Keigo, Yamamura, Yuriko, Hiramatsu, Sumie, Ohashi, Keiji, Morishita, Michiko, Watanabe, Haruki, Matsumoto, Yoshinori, Sunahori-Watanabe, Katsue, Kawabata, Tomoko, Wada, Jun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171234/
https://ncbi.nlm.nih.gov/pubmed/30285859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-018-1817-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia